Antibody Analytics, a Motherwell, Scotland, UK-based contract research organisation (CRO) and provider of immunology research services, received a multi-million-GBP investment from NorthEdge.
The amount of the deal was not disclosed.
The company intends to use the funds to further enhance increased research capabilities, allowing the business to continue to develop new solutions.
Led by CEO Andy Upsall, and Chief Scientific Officer Dr. Agapitos Patakas, Antibody Analytics supports biopharmaceutical companies globally to overcome substantial scientific challenges by providing data of outstanding quality to expedite new healthcare solutions and improve global health outcomes. It is focused on supporting the developers of antibody-targeted therapeutics, complex biologics and immunotherapies, to help their clients get drug candidates into the clinic.
Antibody Analytics has expertise in translational immunology, cell line development, and bioanalytical services, leveraging a wide range of off-the-shelf and custom in vitro assay systems coupled with human donor material to drive breakthroughs in modern patient treatments. With a focus on novel and emerging therapeutic classes, their assay platforms are applicable to oncology, auto-immunity, inflammatory disease and beyond.
The investment was run out of NorthEdge’s Manchester office and led by Jon Pickering, Partner and CIO; Liam May, Director; and Simone Masterson, Investment Manager. Liam May will join the board on behalf of NorthEdge.
FinSMEs
02/11/2023